US-based health technology company Tempus AI has acquired Paige, a digital pathology firm developing artificial intelligence (AI)-driven diagnostic and biomarker software.
The deal, valued at $81.25m, will be settled primarily in Tempus common stock. Tempus is currently listed on Nasdaq.
The acquisition is expected to enhance Tempus’ dataset and expand its technical team.
Also, it will help Tempus strengthen its presence in digital pathology through an advanced technology portfolio.
Paige CEO and chief technology officer Razik Yousfi said: “We’ve always believed that the future of cancer care and precision medicine lies in harnessing the full potential of AI to redefine what’s possible in digital pathology and transform how cancer is detected, understood, and treated.
“By joining forces with Tempus, a company already making remarkable strides in oncology diagnostics, we can bring our innovations to a broader patient population and deliver even greater impact.
“We are confident this partnership is uniquely positioned to maximise and expand the reach of our technology, ensuring it fulfils our mission of delivering powerful, data-driven insights.”
Established in 2017, Paige has been developing advanced AI applications in pathology, including the first US Food and Drug Administration (FDA)-cleared AI tool for cancer detection.
Its in-house dataset includes nearly seven million digitised pathology slides with clinical annotations. This collection, sourced from 45 countries, supports cancer research and advances drug development.
Tempus aims to leverage its library of multimodal data and operating systems to deliver AI-enabled precision medicine solutions.
By integrating Paige’s resources, Tempus seeks to enhance personalised patient care and accelerate therapeutic discovery and development.
Tempus founder and CEO Eric Lefkofsky said: “As we embark upon building the largest foundation model that’s ever been built in oncology, the acquisition of Paige substantially accelerates our efforts.
“Paige is a leader in digital pathology and has amassed one of the most comprehensive digital pathology datasets in the world through its relationship with Memorial Sloan Kettering Cancer Centre.
“We believe both the Paige team, with their deep generative AI experience, and the dataset they have built, will be catalytic across all of our AI efforts.”
Earlier this year, Tempus acquired Deep 6 AI, an AI-powered precision research platform serving healthcare organisations and life sciences companies. Founded in 2016, Deep 6 AI enables healthcare organisations to de-risk trials, accelerate recruitment, and generate real-world evidence (RWE).
